Clinical Takeaway
In this randomized, double-blind, placebo-controlled crossover trial in healthy adults, neither a low nor a high single dose of CBD produced measurable changes in cortical excitability compared to placebo. This suggests that CBD’s well-documented anti-seizure benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome may depend more on its interaction with co-administered medications like clobazam than on a direct brain-quieting effect. Clinicians should keep in mind that CBD’s efficacy in epilepsy treatment likely involves pharmacokinetic rather than purely pharmacodynamic mechanisms.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may be primarily driven by pharmacokinetic interactions with concurrent antiepileptic medications rather than direct effects on neuronal excitability, fundamentally reshaping how clinicians should interpret CBD’s mechanism of action. Understanding that CBD lacks intrinsic cortical effects has important implications for monotherapy decisions and dosing strategies in patients where drug-drug interactions cannot explain therapeutic outcomes. These findings warrant reconsideration of CBD’s role in treatment algorithms and suggest that reported benefits in certain seizure syndromes may depend on specific drug combinations rather than CBD’s independent anti-epileptic properties.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
? This well-designed crossover trial provides useful mechanistic clarity: CBD appears to lack direct effects on cortical excitability when given acutely, suggesting that its clinical seizure-reduction benefits in Dravet and Lennox-Gastaut syndromes may arise primarily through pharmacokinetic interactions with concurrent medications like clobazam rather than through direct GABAergic or other intrinsic neuronal effects. This finding is important because it reframes our understanding of why CBD works in these specific indications and highlights that efficacy data from polypharmacy studies cannot be readily extrapolated to CBD monotherapy contexts. Clinicians should recognize that acute dosing paradigms in controlled trials may differ from steady-state effects or long-term neuroadaptation, and that some of CBD’s purported benefits in other conditions (chronic pain, anxiety, sleep) remain mechanistically unresolved by studies of this design. The practical implication is that CBD should continue to be positioned as an adjunctive agent in approved seiz
| |
Have thoughts on this? Share it:
